Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Molecular profiling and L1CAM expression are crucial for predicting high-risk endometrial cancer recurrence and survival. L1CAM is a significant prognostic factor, especially in p53 abnormal and NSMP groups.
Area Of Science
- Gynecologic Oncology
- Molecular Pathology
- Cancer Genomics
Background
- The prognostic role of molecular classification and L1 cell adhesion molecule (L1CAM) in high-risk endometrial cancer remains unclear.
- Understanding these factors is vital for refining treatment strategies and improving patient outcomes.
Purpose Of The Study
- To investigate the association between molecular profiling (ProMisE classification) and L1CAM expression with recurrence patterns and cancer-specific survival (CSS) in high-risk endometrial cancer.
- To determine the independent prognostic value of L1CAM in relation to established molecular subtypes.
Main Methods
- Retrospective cohort study of 489 patients with high-risk endometrial cancer.
- Molecular classification using ProMisE (POLE, MMRd, p53, NSMP) and L1CAM expression analysis.
- Time to recurrence (TTR) and CSS were the primary endpoints, analyzed using multivariable models.
Main Results
- Of 486 classified patients, molecular subtypes were POLE-mutated (8%), MMRd (30%), p53 abnormal (39%), and NSMP (23%). High L1CAM expression was found in 53% of tumors.
- L1CAM expression was a significant independent predictor for both TTR and CSS in multivariable analysis.
- While ProMisE showed significance for TTR, L1CAM retained significance when included in a model with ProMisE, indicating its distinct prognostic value. POLE-mutated tumors had excellent prognosis; p53 abnormal or high L1CAM tumors had poor prognosis.
Conclusions
- L1CAM serves as an independent adverse prognostic factor in endometrial cancer, particularly within the p53 abnormal and NSMP molecular groups.
- Patients with p53 abnormal or NSMP tumors and high L1CAM expression require specialized attention and potentially intensified adjuvant treatment strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...